Varrieur, Tracy

Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial

de Langen, A. J., Johnson, M. L., Mazieres, J., Dingemans, A.-M. C., Mountzios, G., Pless, M., Wolf, J., Schuler, M., Lena, H., Skoulidis, F., et al. (2023) · The Lancet

Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

Cited by 619

Preclinical development and phase 1 trial of a novel siRNA targeting lipoprotein(a)

Koren, M. J., Moriarty, P. M., Baum, S. J., Neutel, J., Hernandez-Illas, M., Weintraub, H. S., Florio, M., Kassahun, H., Melquist, S., Varrieur, T., et al. (2022) · Nature Medicine

Lipoproteins and Cardiovascular HealthRNA Interference and Gene Delivery

Cited by 239

Sotorasib with panitumumab in chemotherapy-refractory KRASG12C-mutated colorectal cancer: a phase 1b trial

Kuboki, Y., Fakih, M., Strickler, J., Yaeger, R., Masuishi, T., Kim, E. J., Bestvina, C. M., Kopetz, S., Falchook, G. S., Langer, C., et al. (2024) · Nature Medicine

Colorectal Cancer Treatments and StudiesLung Cancer Treatments and Mutations

Cited by 103

OA03.03 sotorasib in combination with RMC-4630, a SHP2 inhibitor, in KRAS p.G12C-mutated NSCLC and other solid tumors

Falchook, G., Li, B. T., Marrone, K. A., Bestvina, C. M., Langer, C. J., Krauss, J. C., Strickler, J. H., Meloni, A., Dai, T., Varrieur, T., et al. (2022) · Journal of Thoracic Oncology

Lung Cancer Treatments and MutationsProtein Tyrosine Phosphatases

Cited by 56